Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew J Yee

Showing results (61-70 of 97) with videos related to

Pageof 10
Sort By:
JACC. Cardiovascular Imaging|December 19, 2021
Myocardial Composition in Light-Chain Cardiac Amyloidosis More Than 1 Year After Successful TherapySarah A M Cuddy, Michael Jerosch-Herold, Rodney H Falk, et al.
Science Translational Medicine|November 4, 2016
Genetic interrogation of circulating multiple myeloma cells at single-cell resolutionJens G Lohr, Sora Kim, Joshua Gould, et al.
Blood Cancer Journal|April 24, 2025
Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomideDiana Cirstea, Rajib Shome, Mehmet Samur, et al.
Blood Cancer Journal|June 29, 2022
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering CommitteeShaji Kumar, Lawrence Baizer, Natalie S Callander, et al.
Blood Advances|January 15, 2025
Nivolumab to restore T-cell fitness in CAR-T refractory multiple myelomaJohannes M Waldschmidt, Noori Sotudeh, Sankalp Arora, et al.
Blood|March 31, 2025
Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatmentViktoria Blumenberg, Benjamin R Puliafito, Charlotte E Graham, et al.
Blood Advances|April 25, 2022
Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myelomaMatthew J Frigault, Michael R Bishop, Jacalyn Rosenblatt, et al.
Frontiers in Cardiovascular Medicine|June 14, 2024
Mechanisms of left ventricular systolic dysfunction in light chain amyloidosis: a multiparametric cardiac MRI studyEthan Katznelson, Michael Jerosch-Herold, Sarah A M Cuddy, et al.
Blood Advances|December 31, 2021
Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 studyGareth P Gregory, Shaji Kumar, Ding Wang, et al.
The Lancet. Oncology|September 21, 2016
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trialAndrew J Yee, William I Bensinger, Jeffrey G Supko, et al.
Pageof 10

Showing results (61-70 of 97) with videos related to

Sort By:
Pageof 10
JACC. Cardiovascular Imaging|December 19, 2021
Myocardial Composition in Light-Chain Cardiac Amyloidosis More Than 1 Year After Successful TherapySarah A M Cuddy, Michael Jerosch-Herold, Rodney H Falk, et al.
Science Translational Medicine|November 4, 2016
Genetic interrogation of circulating multiple myeloma cells at single-cell resolutionJens G Lohr, Sora Kim, Joshua Gould, et al.
Blood Cancer Journal|April 24, 2025
Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomideDiana Cirstea, Rajib Shome, Mehmet Samur, et al.
Blood Cancer Journal|June 29, 2022
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering CommitteeShaji Kumar, Lawrence Baizer, Natalie S Callander, et al.
Blood Advances|January 15, 2025
Nivolumab to restore T-cell fitness in CAR-T refractory multiple myelomaJohannes M Waldschmidt, Noori Sotudeh, Sankalp Arora, et al.
Blood|March 31, 2025
Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatmentViktoria Blumenberg, Benjamin R Puliafito, Charlotte E Graham, et al.
Blood Advances|April 25, 2022
Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myelomaMatthew J Frigault, Michael R Bishop, Jacalyn Rosenblatt, et al.
Frontiers in Cardiovascular Medicine|June 14, 2024
Mechanisms of left ventricular systolic dysfunction in light chain amyloidosis: a multiparametric cardiac MRI studyEthan Katznelson, Michael Jerosch-Herold, Sarah A M Cuddy, et al.
Blood Advances|December 31, 2021
Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 studyGareth P Gregory, Shaji Kumar, Ding Wang, et al.
The Lancet. Oncology|September 21, 2016
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trialAndrew J Yee, William I Bensinger, Jeffrey G Supko, et al.
Pageof 10